Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations.

Cells - 2 Mar 2022

Sidorova Olga Alexandra, Sayed Shady, Paszkowski-Rogacz Maciej, Seifert Michael, Camgöz Aylin, Roeder Ingo, Bornhäuser Martin, Thiede Christian, Buchholz Frank

Abstract excerpt

DNA-methyltransferase 3A (DNMT3A) mutations belong to the most frequent genetic aberrations found in adult acute myeloid leukemia (AML). Recent evidence suggests that these mutations arise early in leukemogenesis, marking leukemic progenitors and stem cells, and persist through consolidation chemotherapy, providing a pool for AML relapse. Currently, there are no therapeutic approaches directed specifically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to DNA (Cytosine-5-)-Methyltransferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methyltransferase 3A

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Proto-Oncogene Proteins

Share to RNA Interference

Source

Open in PubMed Open full text

Identifiers

PMID: 35269477
DOI: 10.3390/cells11050854
PMCID: PMC8909053

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations.PMID 35269477Read ↗

RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drugSemantic proximity Read ↗

Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing.Semantic proximity Read ↗

Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement.Semantic proximity Read ↗

RNAi screening of the tyrosine kinome in primary patient samples of acute myeloid leukemiaSemantic proximity Read ↗

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Semantic proximity Read ↗

USP7 as part of non-canonical PRC1.1 is a druggable target in leukemiaSemantic proximity Read ↗

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia.Semantic proximity Read ↗

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemiaSemantic proximity Read ↗

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsSemantic proximity Read ↗

Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.Semantic proximity Read ↗

The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemiaSemantic proximity Read ↗

miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.